Based on genetic profiling that identified HER2 overexpression and/or amplification/mutation in the tumor, this study reports the first successful case of treating HER2-positive cervical mucosal malignant melanoma with T-DXd in combination with Toripalimab. The gene discussed is ERBB2; the disease is neoplasm.